EDGAR·FLOW

Eloxx Pharmaceuticals, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Eloxx dosed first two patients in Phase 2b EXACT study for nonsense mutation Alport syndrome (topline mid-2027); received IND clearance for Phase 2 EXPRESS study in nonsense mutation ADPKCD with first dosing expected Q3 2027. Cash position $56.3M as of Sept 30, 2026 (down from $62M at June 30). Company appointed T.R. Srinivas, M.D. as SVP/CMO (from Novartis) and added Geno Germano to Board. Q3 2026 net loss $5.5M ($0.49/share); company believes cash sufficient through 2028.
Why this rating

Clinical progress (two ongoing Phase 2 trials, IND clearance) is material for pre-revenue biotech; $56.3M cash runway into 2028 represents ~17x quarterly burn, adequate for near-term milestones. Relative to $330K market cap, company is well-capitalized. Senior leadership additions (CMO, experienced board member) signal execution capability. No transformational event, but concrete advancement of pipeline.

Tradability signal
NO TRADE

No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.43% over 4 hrs, n=488). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$13.15
+10 min · unknown
$12.87 ▼ 2.13%
+30 min · unknown
$12.45 ▼ 5.32%
+1 hr · unknown
$12.39 ▼ 5.78%
+4 hrs · unknown
$11.89 ▼ 9.58%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ ELOX · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.